Bristol Myers Squibb raises 2026 forecast

Bristol Myers Squibb has provided specific 2026 financial guidance, forecasting full-year revenue between $46 billion and $47.5 billion with adjusted EPS expected in the $6.05 to $6.35 range. Additionally, Q1 2026 results exceeded expectations, reporting revenue of $11.5 billion and an adjusted EPS of $1.58. Analyst consensus currently sits at a 'Moderate Buy' among 30 analysts, with Piper Sandler maintaining a 'Buy' rating and a $75 price target.

Bristol Myers Squibb's Q1 2026 revenue rose 2.6% to $11.5 billion, exceeding Street estimates, while adjusted EPS reached $1.58, also surpassing Wall Street forecasts. For the full year 2026, the company expects revenue to fall between $46 billion and $47.5 billion, with adjusted EPS projected in the $6.05 to $6.35 range. Additionally, analysts maintain a 'Moderate Buy' consensus rating, with Piper Sandler's David Amsellem maintaining a 'Buy' rating and a $75 price target as of July 28.

Unverified reports indicate that Bristol Myers Squibb has raised its full-year revenue forecast to a range of $49 billion to $50 billion and increased its 2026 adjusted earnings forecast to $6.75–$7.00 per share, up from the previous $6.05–$6.35 range. Additionally, the company's annual Eliquis sales growth forecast has reportedly been raised to 20%–25% from an earlier projection of 10%–15%.

Bristol-Myers Squibb has reportedly raised its full-year revenue forecast to a range of $49 billion to $50 billion, and its adjusted 2026 earnings forecast to $6.75–$7.00 per share, up from the previous guidance of $6.05–$6.35. Additionally, the company unverifiedly increased its annual Eliquis sales growth projection to 20%–25%, compared to the prior 10%–15% estimate. Second-quarter revenue is also reported to have reached $12.97 billion, representing a 6% increase from the previous year.

Unverified reports indicate that Bristol Myers Squibb has raised its full-year revenue forecast to a range of $49 billion to $50 billion and increased its 2026 adjusted earnings guidance to $6.75–$7.00 per share, up from the previous $6.05–$6.35 range. Additionally, the company's annual Eliquis sales growth forecast has reportedly been upgraded to 20%–25% from its prior 10%–15% projection.

Bristol-Myers Squibb has reportedly raised its full-year 2026 revenue forecast to a range of $49 billion to $50 billion and increased its adjusted earnings forecast to $6.75–$7.00 per share, up from the previous guidance of $6.05–$6.35. Unverified reports also indicate that the annual Eliquis sales growth forecast was raised to 20%–25% from an earlier projection of 10%–15%. Additionally, second-quarter revenue reached $12.97 billion, exceeding analyst estimates of $11.75 billion, while adjusted earnings per share rose to $2.04, surpassing the $1.59 expectation.